ArticleBMC pediatrics2026
Association between 23S rRNA gene positivity and clinical characteristics in patients with mycoplasma pneumoniae pneumonia.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the clinical characteristics of children with Mycoplasma pneumoniae pneumonia (MPP) who are positive for 23 S rRNA resistance genes and their correlation with 23 S rRNA resistance genes, providing evidence for the precise diagnosis and treatment of pediatric MPP.
methodA total of 210 pediatric patients diagnosed with MPP and admitted to our hospital between January 2024 and November 2025 were enrolled in this study. Clinical manifestations were compared between patients positive (positive group) and negative (negative group) for the 23 S rRNA gene. Logistic regression analysis was performed to identify independent predictive factors associated with severe MPP (SMPP).
resultsThe overall drug resistance rate was 27.6%, with 58 of 210 pediatric patients testing positive. The positive group exhibited significantly higher rates of extrapulmonary manifestations, longer duration of fever and cough, and prolonged hospital stays compared to the negative group. Additionally, heparin-binding protein (HBP), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), and immunoglobulin levels were significantly higher in the positive group. Logistic regression analysis indicated that elevated HBP and IgG levels, 23 S rRNA gene positivity were independent risk factors for adverse outcomes.
conclusionPediatric patients with MPP who are positive for the 23 S rRNA drug-resistance gene are associated with more severe clinical manifestations and heightened inflammatory responses. HBP levels, IgG, and 23 S rRNA gene positivity may serve as important indicators for disease severity assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.